ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Infection-related Rheumatic Disease Poster (1530–1564)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM
Abstract Number: 1560
A Multidisciplinary Timely Approach to Initiate Immunosuppressive Biologic Therapy and Improve COVID-19 Cytokine Storm Syndrome Outcome
8:30AM-10:30AM
Abstract Number: 1536
Acceptability of Vaccines Against COVID-19 and Other Preventable Infections Among Patients with Rheumatic Disease
8:30AM-10:30AM
Abstract Number: 1538
Adverse Events After SARS-CoV-2 Vaccination Among Rheumatology Outpatients in New York City
8:30AM-10:30AM
Abstract Number: 1540
Antibody Response After SARS-CoV-2 Infection in Patients with Rheumatic Diseases: A Multicenter, Nationwide Study
8:30AM-10:30AM
Abstract Number: 1562
B Cell Reconstitution Is Strongly Associated with COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Treated with Rituximab
8:30AM-10:30AM
Abstract Number: 1563
Clinical Characteristics and Management of Olecranon and Prepatellar Septic Bursitis in a Multicenter Study
8:30AM-10:30AM
Abstract Number: 1544
Clinical Course and Risk Factors for Severe/Critical COVID-19 in Patients with Rheumatic Diseases – a Multicenter, Nationwide Study
8:30AM-10:30AM
Abstract Number: 1555
Clinical Outcomes of Coronavirus Disease-2019 (COVID-19) in Hospitalized Patients with Rheumatic and Musculoskeletal Diseases (RMD)
8:30AM-10:30AM
Abstract Number: 1533
Comparison of Hospitalization and Mortality Rate in Patients with Different Rheumatic Diseases: A Brazilian Registry Cross-Sectional Analysis
8:30AM-10:30AM
Abstract Number: 1554
COVID-19 Vaccine Hesitancy Among Patients with Rheumatic and Other Diseases
8:30AM-10:30AM
Abstract Number: 1542
Does Adjustment to Dosing and Timing of Immunomodulatory Drugs Impact Immunogenicity of COVID19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Disease (AIIRD)?
8:30AM-10:30AM
Abstract Number: 1543
Epidemiology and Disease Burden of Hospitalized Children with Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 Infection in Canada: A Canadian Pediatric Surveillance Program National Prospective Study
8:30AM-10:30AM
Abstract Number: 1530
Evaluation of the Possible Different Evolution of SARS-CoV-2 Infection with Tumor Necrosis Factor Inhibitors or with Rituximab in Rheumatic Patients
8:30AM-10:30AM
Abstract Number: 1549
Experience from a Diverse Rheumatology Cohort with COVID-19: Are We Doing Better Than We Expected?
8:30AM-10:30AM
Abstract Number: 1550
Flares and Side Effects After COVID-19 Vaccination in Patients with Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 1551
Generation of Autoantibodies and Their Association with Rheumatic Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Adult Population Following BNT162b2 mRNA Covid-19 Vaccination
8:30AM-10:30AM
Abstract Number: 1539
High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients
8:30AM-10:30AM
Abstract Number: 1546
Immune Responses to COVID-19 Vaccines in Patients Using Immunosuppressive Medication for Inflammatory Arthritis – An Observational Study of 1500 Patients
8:30AM-10:30AM
Abstract Number: 1557
Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases
8:30AM-10:30AM
Abstract Number: 1537
Impact of COVID-19 Infection on Patient-Reported Outcomes in Rheumatic Disease Patients: A Cross Sectional Study
8:30AM-10:30AM
Abstract Number: 1535
Low Incidence and Transient Elevation of Autoantibodies Post mRNA COVID-19 Vaccination
8:30AM-10:30AM
Abstract Number: 1553
Low-dose Tocilizumab in the Treatment of COVID-19 Pneumonitis: 90-day Mortality Follow-up
8:30AM-10:30AM
Abstract Number: 1532
Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease
8:30AM-10:30AM
Abstract Number: 1556
Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)
8:30AM-10:30AM
Abstract Number: 1564
Nailfold Capillaroscopy Characterization in COVID-19: A Case Control Study
8:30AM-10:30AM
Abstract Number: 1531
New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19
8:30AM-10:30AM
Abstract Number: 1547
Potential Predictors of Outcome for Anakinra Treatment in COVID-19 Patients with Macrophage Activation Syndrome
8:30AM-10:30AM
Abstract Number: 1559
Potential Predictors of Requirement for Mechanical Ventilation in Cases of COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C): Results of a Hospital-based Cohort Study from South India
8:30AM-10:30AM
Abstract Number: 1541
Preliminary Criteria for Macrophage Activation Syndrome Associated with Coronavirus Disease-19
8:30AM-10:30AM
Abstract Number: 1561
Prevalence of SARS-CoV2 Infection in Diseases Inflammatory Rheumatology in the Rheumatology Service of the Hospital Docente Padre Billini, Dominican Republic
8:30AM-10:30AM
Abstract Number: 1548
Q Fever as a Mimicker of Rheumatologic Conditions: A Case Series from Two Tertiary Care Academic Centers in Southern California
8:30AM-10:30AM
Abstract Number: 1545
Safety of JAK Inhibitor in Patients with Rheumatoid Arthritis Who Developed Reactivation of Herpes Zoster Virus After Receiving JAK Inhibitor
8:30AM-10:30AM
Abstract Number: 1534
Severity Factors of Covid-19 Infection in Rheumatic Immune-mediated Inflammatory Diseases: Study in a Single University Hospital
8:30AM-10:30AM
Abstract Number: 1552
Systemic Autoimmune Conditions and Hospital Admissions in Covid-19 Infection
8:30AM-10:30AM
Abstract Number: 1558
Therapy Based Outcomes in Patients with Multisystem Inflammatory Syndrome in Children: A Single Center Study

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology